Why Our Mission Still Matters
Modern anesthesia has reached a plateau. Large companies have stepped away, leaving the field with little forward motion, not because innovation is not needed, but because the path is difficult. That is exactly why Expanesthetics exists.
We are the icebreaker at the edge of this frozen ocean. Our proprietary screening process has already identified multiple drug candidates with dramatically improved cardiovascular stability and faster kinetics than existing agents. We are proving that "better" is possible and repeatable using targeted, evidence-driven scientific discovery instead of brute force screening.
No one else is doing this work.
If new inhaled anesthetics are going to be discovered in the current climate, they will come from the team we are building: focused, methodical, resilient, and unwilling to accept "good enough" as the end of the story.
A Decade of Progress
Expanesthetics was born from a breakthrough scientific discovery at UC Davis: the idea that a compound's molar water solubility could predict how it will interact with neuroreceptors in the body, including those involved in anesthesia. That concept led to a new way to identify novel inhaled anesthetics.
Over more than a decade of work, we validated our approach in collaboration with clinicians and global experts, demonstrating multiple compounds that induce anesthesia with increased cardiovascular stability, faster kinetics, and signals of analgesic effect.
We are now advancing the next phase of this mission: expanding anesthetic choice for patients and clinicians worldwide. With disciplined discovery, a strategic publishing effort, and a growing anesthesiologist community behind us, Expanesthetics is uniquely positioned to lead the next era of anesthetic innovation.